COLLABORATION WITH ZYDUS CADILA EXPIRES – KARO BIO CONTINUES TO DEVELOP SAFER GLUCOCORTICOIDS
STOCKHOLM, 2 April 2012 – Karo Bio AB (publ) and the Indian pharmaceutical company Zydus Cadila have decided not to further extend their joint glucocorticoid receptor research and development program. Karo Bio focuses its continued development towards a previously not described mechanism of glucocorticoid regulation.In early 2008, Karo Bio and Zydus Cadila initiated a collaboration to discover and develop novel, selective glucocorticoids for the treatment of inflammatory diseases. The collaboration has generated novel anti-inflammatory compounds with high affinity to the glucocorticoid